Celldex Therapeutics, Inc. (CLDX): R&D Expense
$245.07M
Year ended 2025-12-31
$278.81M
Trailing 12 months to 2026-06-30
+43.9%
3-year compound annual growth
+41.9%
5-year compound annual growth
+9.4%
10-year compound annual growth
| Period ended | R&D Expense | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $245.07M | +49.8% | 2026-02-25, From 2025-01-01 |
| 2024-12-31 | $163.55M | +38.6% | 2026-02-25, From 2024-01-01 |
| 2023-12-31 | $118.01M | +43.5% | 2026-02-25, From 2023-01-01 |
| 2022-12-31 | $82.26M | +54.3% | 2025-02-27, From 2022-01-01 |
| 2021-12-31 | $53.31M | +25.3% | 2024-02-26, From 2021-01-01 |
| 2020-12-31 | $42.53M | -0.3% | 2023-02-28, From 2020-01-01 |
| 2019-12-31 | $42.67M | -35.8% | 2022-02-28, From 2019-01-01 |
| 2018-12-31 | $66.45M | -30.9% | 2021-03-29, From 2018-01-01 |
| 2017-12-31 | $96.17M | -6.4% | 2020-03-26, From 2017-01-01 |
| 2016-12-31 | $102.73M | +2.6% | 2019-03-07, From 2016-01-01 |
| 2015-12-31 | $100.17M | -4.0% | 2018-03-07, From 2015-01-01 |
| 2014-12-31 | $104.38M | +54.9% | 2017-03-14, From 2014-01-01 |
| 2013-12-31 | $67.40M | +42.2% | 2016-02-25, From 2013-01-01 |
| 2012-12-31 | $47.40M | +46.1% | 2015-02-24, From 2012-01-01 |
| 2011-12-31 | $32.44M | +17.3% | 2014-03-03, From 2011-01-01 |
| 2010-12-31 | $27.65M | +5.7% | 2013-03-08, From 2010-01-01 |
| 2009-12-31 | $26.17M | n/a | 2012-03-08, From 2009-01-01 |
R&D Expense at similar companies
| Company | Year ended | R&D Expense | Change YoY |
|---|---|---|---|
| Celldex Therapeutics, Inc. (CLDX) | 2025-12-31 | $245.07M | +49.8% |
| Volitionrx Ltd (VNRX) | 2025-12-31 | $10.08M | -30.0% |
| Insight Molecular Diagnostics Inc. (IMDX) | 2025-12-31 | $15.90M | +61.6% |
| Biomerica Inc (BMRA) | 2026-05-31 | $788.0K | -23.0% |
| Anbio Biotechnology (NNNN) | 2025-12-31 | $201.3K | -55.7% |
| Aspira Women's Health Inc. (AWHL) | 2025-12-31 | $2.88M | -11.9% |
| Immucell Corp (ICCC) | 2025-12-31 | $3.04M | -22.0% |
| Alpha Teknova, Inc. (TKNO) | 2025-12-31 | $2.20M | -20.4% |
| Intellia Therapeutics, Inc. (NTLA) | 2025-12-31 | $388.86M | -16.6% |
Compare CLDX, VNRX, IMDX, BMRA side by side · Screen every company in In Vitro & In Vivo Diagnostic Substances ↗